2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-147626
    GLP-1R agonist 13 2768016-72-2 98%
    GLP-1R agonist 13 (Compound 24) is a GLP-1 receptor agonist.
    GLP-1R agonist 13
  • HY-147627
    GLP-1R agonist 14 2758666-01-0 98%
    GLP-1R agonist 14 (Compound 14) is a GLP-1 receptor agonist with an EC50 of 0-20 nM against h-GLP-1.
    GLP-1R agonist 14
  • HY-147628
    GLP-1R agonist 15 2763621-11-8 98%
    GLP-1R agonist 15 (Compound 101) is a GLP-1 receptor agonist.
    GLP-1R agonist 15
  • HY-147629
    GLP-1R agonist 16 2763329-13-9 98%
    GLP-1R agonist 16 (Compound 115a) is a GLP-1 receptor agonist with an EC50 of 0.15 nM.
    GLP-1R agonist 16
  • HY-147645
    FBPase-IN-2 127143-25-3 98.47%
    FBPase-IN-2 (Compound HS36) is a covalent FBPase inhibitor with an IC50 value of 0.15 μM for wild-type FBPase. FBPase-IN-2 inhibits glucose production in primary mouse hepatocytes via gluconeogenesis modulation. FBPase-IN-2 can be used for the research of type 2 diabetes mellitus.
    FBPase-IN-2
  • HY-147678
    GPR40 agonist 5 2443384-60-7 98%
    GPR40 agonist 5 (compound I-14) is an orally active and potent GPR40 (G protein coupled receptor 40) agonist, with an EC50 of 47 nM. GPR40 agonist 5 decreases the levels of blood glucose and improves the glucose tolerance. GPR40 agonist 5 has sufficient effectiveness for the control of hyperglycemia state in type 2 diabetic mice. GPR40 agonist 5 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    GPR40 agonist 5
  • HY-147711
    α-Amylase/α-Glucosidase-IN-1 329783-03-1 98%
    α-Amylase/α-Glucosidase-IN-1 (compound 33) is a potent α-amylase/α-glucosidase inhibitor with IC50s of 2.01, 2.09 µM for α-amylase and α-glucosidase, respectively. Kinetic studies predict that α-Amylase/α-Glucosidase-IN-1 has the potential of anti hyperglycemia.
    α-Amylase/α-Glucosidase-IN-1
  • HY-147718
    α-Glucosidase-IN-5 111316-33-7 98%
    α-Glucosidase-IN-5 (compound 8) is a potent α-glucosidase inhibitor with an IC50 of 57.9 µM. α-Glucosidase-IN-5 has the potential for the research of diabetes mellitus.
    α-Glucosidase-IN-5
  • HY-14773S
    (Rac)-Mirabegron-d5 1215807-38-7 98%
    (Rac)-Mirabegron-d5 is a deuterium labeled (Rac)-Mirabegron. (Rac)-Mirabegron is the racemate of Mirabegron. Mirabegron is a selective β3-adrenoceptor agonist.
    (Rac)-Mirabegron-d5
  • HY-147757
    PPARγ/δ modulator 1 2089159-00-0 98%
    PPARγ/δ modulator 1 (compound 3e) is a potent PPAR modulator. PPARγ/δ modulator 1 is a PPARδ antagonist and a PPARγ partial agonist , with Ki values of 14.4 nM and 5.31 μM, respectively. PPARγ/δ modulator 1 has the EC50 of 7.3 and 12.6 μM for PPARδ corepression and adiponectin production, respectively.
    PPARγ/δ modulator 1
  • HY-147821
    CB1-IN-2 2527805-39-4 98%
    CB1-IN-2 (Compound 4g) is a selective CB1 inhibitor with an IC50 of 0.644 μM. CB1-IN-2 can penetrates BBB and might cause CNS side effect similar with Rimonabant.
    CB1-IN-2
  • HY-147823
    α-Glucosidase-IN-6 2497685-29-5 98%
    α-Glucosidase-IN-6 (compound 18) is a competitive α-glucosidase inhibitor with an IC50 of 5.69 µM. α-Glucosidase-IN-6 has anti-diabetic potential.
    α-Glucosidase-IN-6
  • HY-147875
    Aldose reductase-IN-6 2470019-41-9 98%
    Aldose reductase-IN-6 (Compound 3) is a competitive aldose reductase (AR) inhibitor with an IC50 of 3.164 μM and a Ki of 0.018 μM. Aldose reductase-IN-6 exhibits no cytotoxicity against healthy cells.
    Aldose reductase-IN-6
  • HY-147879
    α-Glucosidase-IN-8 2448345-96-6 98%
    α-Glucosidase-IN-8 (Compound 4k) is a competitive α-glucosidase inhibitor with an IC50 of 0.18 µg/mL.
    α-Glucosidase-IN-8
  • HY-147927
    Human enteropeptidase-IN-1 1802891-20-8 98%
    Human enteropeptidase-IN-1 (compound 6b) is a highly potent, orally active and low systemic exposure enteropeptidase inhibitor. Human enteropeptidase-IN-1 boosts the increase in fecal protein output, and exhibits potent body weight loss in diet-induced obese (DIO) rat model. Human enteropeptidase-IN-1 can be used for anti-obesity research.
    Human enteropeptidase-IN-1
  • HY-147931
    Human enteropeptidase-IN-2 3031537-31-9 98%
    Human enteropeptidase-IN-2 (compound 1c) is a highly potent enteropeptidase inhibitor. Human enteropeptidase-IN-2 can be used for anti-obesity research.
    Human enteropeptidase-IN-2
  • HY-14794S
    Dextromilnacipran-d6 1127352-73-1 98%
    Dextromilnacipran-d6 is the deuterium labeled Dextromilnacipran (HY-14794). Dextromilnacipran ((1R,2S)-Milnacipran; F2696) is an orally active Serotonin (HY-B1473A)/Noradrenaline (HY-13715) transporter inhibitor. Dextromilnacipran inhibits Serotonin and Noradrenaline reuptake. Dextromilnacipran can be used for the research of depression, fibromyalgia.
    Dextromilnacipran-d6
  • HY-147954
    α-Glycosidase-IN-1 2428389-66-4 98%
    α-Glycosidase-IN-1 (compound MZ7) is a potent α-GLY (α-Glycosidase) inhibitor, with an IC50 of 44.72 nM and a KI of 41.74 nM. α-Glycosidase-IN-1 also shows inhibition profile against human carbonic anhydrase isoenzymes I and II (hCA I and hCA II), and acetylcholinesterase (AChE), with IC50 values of 104.87, 100.04, and 654.87 nM, respectively. α-Glycosidase-IN-1 can be used for the research of many diseases such as diabetes, Alzheimer’s disease, heart failure, ulcer, and epilepsy.
    α-Glycosidase-IN-1
  • HY-147955
    hCAI/II-IN-5 2428389-67-5 98%
    hCAI/II-IN-5 (compound MZ8) is a potent hCA I and hCA II (human carbonic anhydrase isoenzymes I and II) inhibitor, with IC50 values of 37.88 and 45.23 nM, respectively. hCAI/II-IN-5 also shows inhibition profile against α-Glycosidase and AChE, with IC50 values of 48.98 and 420.14 nM, respectively. hCAI/II-IN-5 can be used for the research of many diseases such as diabetes, Alzheimer’s disease, heart failure, ulcer, and epilepsy.
    hCAI/II-IN-5
  • HY-147956
    hCA VB-IN-1 98%
    hCA VB-IN-1 (compound 15) is a potent and selective hCA VB (carbonic anhydrase) inhibitor, with a KI of 515.7 nM.
    hCA VB-IN-1
Cat. No. Product Name / Synonyms Application Reactivity